Eylea aflibercept ophthalmic solution regulatory update

FDA accepted and granted Priority Review to an sBLA from Regeneron for Eylea aflibercept to treat diabetic retinopathy in patients with diabetic macular edema (DME). The PDUFA date is

Read the full 295 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE